Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.

Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.

Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.

Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.

Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.

Abstract: A transmitter has a transmit chain that is configured to format transmit data into a frame structure that comprises signal blocks interspersed with training sequences for assisting a receive operation. The transmit chain is configured to insert two training sequences between a signal block and its following signal block in the frame structure. The transmitter also comprises a sequence generator configured to form the two training sequences, and in particular to form them such that a first of the training sequences is a negative of the second. Having one training sequence being the negative of the other helps to avoid the Direct Current (DC) subcarrier and provides good properties for channel estimation.

Abstract: Provided herein are glass based articles comprising SiO2 in a range from about 20 mol % to about 80 mol %; Al2O3 in a range from about 2 mol % to about 60 mol %; MgO; Li2O; La2O3 in an amount greater than or equal to about 3 mol %; a sum of alkali metal oxides (R2O) is greater than or equal to about 6 mol %; and a sum of MgO and Al2O3 is greater than or equal to about 28 mol %, wherein the glass based article is free of BeO.

Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.

Abstract: Provided herein are variants of fibroblast growth factor 19 (FGF19) proteins and peptide sequences (and peptidomimetics) and fusions of FGF19 and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), and variants of fusions of FG-F19 and/or FGF21 proteins and peptide sequences (and peptidomimetics). In some embodiments, these variants and fusions modulate bile acid homeostasis, and are useful in treatment of bile acid related and associated disorders. In some embodiments, these variants and fusions have glucose lowering activity, and are useful in treatment of hyperglycemia and other disorders.

Abstract: A method for receiving device position determination includes receiving beamformed position reference signals (BF-PRSs) on a plurality of communications beams from at least two transmitting devices in accordance with a BF-PRS configuration, making at least one observed time difference of arrival (OTDOA) measurement in accordance with the BF-PRSs on the plurality of communications beams, and transmitting OTDOA feedback including the at least one OTDOA measurement.

Abstract: The present disclosure involves systems, software, and computer implemented methods for performing dynamic topology switch in a failover operation. In one example, a failover of a first node is determined. The first node includes a first data server and a first replication server. At least one user application connects to the first data server prior to the failover of the first node. In response to the determined failover, the at least one user application is connected to a second data server of a second node. The second node includes the second data server and a second replication server. Prior to the failover of the first node, a data replication topology of the second node is a remote topology. During the failover, if the first replication server on the first node is down, the data replication topology of the second node is switched from the remote topology to a local topology.

Abstract: A method for controlling a transmit power of a terminal, and a terminal, where the method and the terminal include, working states of a first antenna and a second antenna may be monitored, and then a transmit power of the first antenna or that of the second antenna may be controlled according to a preset correspondence. Therefore, according to the method and the terminal, a transmit power of an antenna in a working state in the first antenna and the second antenna may be accurately controlled. If the transmit power is less than a standard transmit power, a Specific Absorption Rate (SAR) can be reduced.

Abstract: A push-button on a device includes a shell of the device, an internal locking portion to connect with the device, a touch pole far away from the locking portion, and a supporting flange portion extending from the internal surface of the shell. The supporting flange portion and the device support each other. When the shell is pressed, the push-button elastically deforms as the locking portion 103 acts as a fixing point and the supporting end acts as a supporting point. The touch pole moves with the shell and the switch on a PCB is triggered to generate at least one signal.

Abstract: An analog beamforming transmitter includes: a plurality of beamforming transmission circuits coupled in parallel between a signal input and an array of antenna ports, wherein the signal input is configured to receive an analog complex-valued communication signal having an in-phase and a quadrature component, wherein each antenna port of the array of antenna ports is configured to provide a dual-polarized antenna signal having a first polarization component and a second polarization component, wherein each beamforming transmission circuit is coupled between the signal input and a respective antenna port of the array of antenna ports, wherein each beamforming transmission circuit comprises a first coefficient input for receiving a first analog complex-valued beamforming coefficient a set of first analog complex-valued beamforming coefficients and a second coefficient input for receiving a second analog complex-valued beamforming coefficient of a set of second analog complex-valued beamforming coefficients.

Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.

Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.

Abstract: A spectrum manager for allocating a shared frequency spectrum in a wireless communication system is disclosed. The wireless communication system comprises a plurality of base stations which are operated by at least two operators, said spectrum manager being configured to group the plurality of base stations into clusters based on spectrum demand related information; and determine a spectrum partition pattern for each cluster based on the spectrum demand related information and information of the grouped based station clusters, a spectrum partition pattern specifying the partition and allocation of frequency spectrum fragments to said at least two operators in a corresponding cluster, wherein a frequency spectrum fragment is allocated to only one of said at least two operators in each cluster, and forward information regarding the spectrum partition pattern to the plurality of base stations or to one or a plurality of network entities of the at least two operators.

Abstract: Provided herein are methods of using 7a-hydroxy-4-cholsten-3-one (C4) in predicting the clinical sensitivity to treatment of bile acid-related and associated disorders with treatment peptides, such as variants of fibroblast growth factor 19 (FGF19) proteins and peptide sequences (and peptidomimetics) and fusions of FGF19 and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), and variants of fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics).

Abstract: The present invention provides methods for preventing, attenuating neuronal damage or stimulating neuronal repair prior or following central nervous system injury.

Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FG-F21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.